Attorney General Pam Bondi revealed that she carries around a vial of fake fentanyl to show that just a tiny amount can kill, while warning parents of the “monsters” their children may be ...

Additionally, findings from the LINKER-MM2 trial, which examines combinations of the investigational BCMAxCD3 bispecific antibody linvoseltamab with proteasome inhibitors in relapsed/refractory ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab for relapsed or refractory multiple myeloma. Other research ...

“Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has ...

Q1 earnings and revenue miss expectations, mainly due to falling EYLEA sales. Stock rises on optimism around new drug approvals, pipeline progress, and upcoming FDA decisions. Don’t miss this ...

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for adults with relapsed and refractory multiple myeloma. This approval ...

While staring longingly out of the window in her apartment in Coruscant, the mechanic from Ferrix opens a small gray canister and takes a few drops of some blue liquid from a vial as the music ...

While the partnership with Sanofi for new pipeline products has been scaled back, this gives Regeneron several in-house opportunities, like bispecifics odronextamab (lymphoma) and linvoseltamab ...